FABIOR (tazarotene) by Design Pharmaceuticals is form, the cognate carboxylic acid of tazarotene, by rapid deesterification in animals and man. First approved in 2012.
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
FABIOR (tazarotene) is a topical retinoid foam formulation that treats acne vulgaris through selective binding to retinoic acid receptors (RARβ and RARγ). It works via anti-hyperproliferative, anti-inflammatory, and keratinocyte-normalizing mechanisms to reduce corneocyte accumulation and improve skin differentiation.
FABIOR faces significant competitive pressure (8/10) and near-term patent expiry, suggesting a contracting brand team and shift toward defensive strategy rather than growth initiatives.
form, the cognate carboxylic acid of tazarotene, by rapid deesterification in animals and man. Tazarotenic acid binds to all 3 members of the retinoic acid receptor (RAR) family: RARα, RARβ, and RARγ but shows relative selectivity for RARβ and RARγ and may modify gene expression. The clinical…
Retinoid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions
A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris
Efficacy and Safety of Tazarotene Gel in Nail Psoriasis
A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.
Worked on FABIOR at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~4 years — strategic planning for patent cliff underway
FABIOR offers limited career momentum; with zero linked job postings and a product in LOE approaching phase, roles are primarily focused on defending market share and managing transition to generic competition. Career development is constrained by modest scale ($79K Part D spend) and high competitive pressure, making this a consolidation rather than growth opportunity.